AU2011214135B2 - Sanglifehrin based compounds - Google Patents

Sanglifehrin based compounds Download PDF

Info

Publication number
AU2011214135B2
AU2011214135B2 AU2011214135A AU2011214135A AU2011214135B2 AU 2011214135 B2 AU2011214135 B2 AU 2011214135B2 AU 2011214135 A AU2011214135 A AU 2011214135A AU 2011214135 A AU2011214135 A AU 2011214135A AU 2011214135 B2 AU2011214135 B2 AU 2011214135B2
Authority
AU
Australia
Prior art keywords
single bond
represented
following structure
rxs
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011214135A
Other languages
English (en)
Other versions
AU2011214135A1 (en
Inventor
Matthew Alan Gregory
Christine Janet Martin
Steven James Moss
Barrie Wilkinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abliva AB
Original Assignee
Neurovive Pharmaceutical AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1002097.2A external-priority patent/GB201002097D0/en
Priority claimed from GBGB1006128.1A external-priority patent/GB201006128D0/en
Priority claimed from GBGB1101085.7A external-priority patent/GB201101085D0/en
Application filed by Neurovive Pharmaceutical AB filed Critical Neurovive Pharmaceutical AB
Publication of AU2011214135A1 publication Critical patent/AU2011214135A1/en
Assigned to NEUROVIVE PHARMACEUTICAL AB reassignment NEUROVIVE PHARMACEUTICAL AB Request for Assignment Assignors: BIOTICA TECHNOLOGY LIMITED
Application granted granted Critical
Publication of AU2011214135B2 publication Critical patent/AU2011214135B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
AU2011214135A 2010-02-09 2011-02-09 Sanglifehrin based compounds Ceased AU2011214135B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1002097.2 2010-02-09
GBGB1002097.2A GB201002097D0 (en) 2010-02-09 2010-02-09 Novel compounds
GBGB1006128.1A GB201006128D0 (en) 2010-04-13 2010-04-13 Novel compounds
GB1006128.1 2010-04-13
GB1101085.7 2011-01-21
GBGB1101085.7A GB201101085D0 (en) 2011-01-21 2011-01-21 Novel compounds
PCT/GB2011/050236 WO2011098809A1 (en) 2010-02-09 2011-02-09 Sanglifehrin based compounds

Publications (2)

Publication Number Publication Date
AU2011214135A1 AU2011214135A1 (en) 2012-08-23
AU2011214135B2 true AU2011214135B2 (en) 2014-07-31

Family

ID=43836693

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011214135A Ceased AU2011214135B2 (en) 2010-02-09 2011-02-09 Sanglifehrin based compounds

Country Status (9)

Country Link
US (1) US9119853B2 (https=)
EP (1) EP2533784B1 (https=)
JP (1) JP5894935B2 (https=)
AU (1) AU2011214135B2 (https=)
BR (1) BR112012019866A8 (https=)
CA (1) CA2788761C (https=)
ES (1) ES2541853T3 (https=)
MX (1) MX2012008873A (https=)
WO (1) WO2011098809A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201008123D0 (en) * 2010-05-17 2010-06-30 Biotica Tech Ltd Novel compounds
JO3063B1 (ar) * 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه
GB201118334D0 (en) * 2011-10-24 2011-12-07 Biotica Tech Ltd Novel dosage form
WO2018091634A1 (en) 2016-11-18 2018-05-24 Neurovive Pharmaceutical Ab Use of sanglifehrin macrocyclic analogues as anticancer compounds
KR20210116479A (ko) * 2018-12-21 2021-09-27 레볼루션 메디슨즈, 인크. 공동 결합에 참여하는 화합물 및 그의 용도
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
AU2022268962A1 (en) 2021-05-05 2023-12-14 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR006514A1 (es) 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
US6124453A (en) 1995-07-04 2000-09-26 Novartis Ag Macrolides
AP1029A (en) 1996-07-05 2001-12-11 Biotica Tech Limited Erythromycins and process for their preparation.
GB9814622D0 (en) 1998-07-06 1998-09-02 Biotica Tech Ltd Polyketides,their preparation,and materials for use therein
US20090221598A1 (en) 2005-06-17 2009-09-03 Kai Lin Use of Sanglifehrin in HCV
CA2674296C (en) 2007-01-04 2015-11-24 Debiopharm Sa Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy
EP2342335B1 (en) 2008-09-24 2015-09-16 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Novel gene cluster
JO3063B1 (ar) 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SEDRANI, R. et al, J. Am. Chem. Soc., 2003, vol. 125, pp. 3849-3859 *

Also Published As

Publication number Publication date
CA2788761A1 (en) 2011-08-18
WO2011098809A1 (en) 2011-08-18
CA2788761C (en) 2018-05-29
BR112012019866A8 (pt) 2017-12-26
JP2013518923A (ja) 2013-05-23
JP5894935B2 (ja) 2016-03-30
BR112012019866A2 (pt) 2017-07-11
US20120295841A1 (en) 2012-11-22
MX2012008873A (es) 2012-11-22
AU2011214135A1 (en) 2012-08-23
CN102770139A (zh) 2012-11-07
EP2533784A1 (en) 2012-12-19
EP2533784B1 (en) 2015-04-22
ES2541853T3 (es) 2015-07-27
US9119853B2 (en) 2015-09-01

Similar Documents

Publication Publication Date Title
AU2011214135B2 (en) Sanglifehrin based compounds
CA2830831C (en) Macrocyclic compounds and methods for their production
WO2011098808A1 (en) Sanglifehrin based compounds
WO2011098805A1 (en) Sanglifehrin based compounds
WO2011144924A1 (en) Amine or amid analogues of sanglifehrin
CN102770139B (zh) 基于Sanglifehrin的化合物
HK1189237B (en) Macrocyclic compounds and methods for their production
HK1189236B (en) Macrocyclic compound and methods for its production
AU2011346823A1 (en) Sanglifehrin derivatives and methods for their production

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NEUROVIVE PHARMACEUTICAL AB

Free format text: FORMER APPLICANT(S): BIOTICA TECHNOLOGY LIMITED

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired